U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Henderson JT, Webber EM, Weyrich M, et al. Screening for Breast Cancer: A Comparative Effectiveness Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2024 Apr. (Evidence Synthesis, No. 231.)

Cover of Screening for Breast Cancer: A Comparative Effectiveness Review for the U.S. Preventive Services Task Force

Screening for Breast Cancer: A Comparative Effectiveness Review for the U.S. Preventive Services Task Force [Internet].

Show details

References

1.
Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(4):279–296. [PubMed: 26757170]
2.
The Breast : Comprehensive Management of Benign and Malignant Disorders, 3rd Edition. Vol 3. St. Louis: WB Saunders; 2004.
3.
Dillon D, Guidi A, Schnitt S. Ch 25: Pathology of Invasive Breast Cancer. In: Harris J, Lippman M, Morrow M, Osborne C, eds. Diseases of the Breast. 5th ed. Philadelphia: Lippincott-Williams & Wilkins; 2014.
4.
Corben A, Brogi E. Ch 21: Ductal Carcinoma In Situ and Other Intraductal Lesions: Pathology, Immunochemistry, and Molecular Alterations. In: Harris J, Lippman M, Morrow M, Osborne C, eds. Diseases of the Breast. 5th ed. Philadelphia: Lippincott-Williams & Wilkins; 2014.
5.
Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430–1441. [PubMed: 15070793]
6.
King T, Reis-Filho J. Ch 22: Lobular Carcinoma In Situ: Biology and Management. In: Harris J, Lippman M, Morrow M, Osborne C, eds. Diseases of the Breast. 5th ed. Philadelphia: Lippincott-Williams & Wilkins; 2014.
7.
Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102. [PubMed: 12867108]
8.
Schwartz G. Biology and Management of Lobular Carcinoma In Situ of the Breast. In: Bland K, Copeland E, eds. The Breast : Comprehensive Management of Benign and Malignant Disorders, 3rd Edition. 3rd ed. St Louis: Saunders; 2004.
9.
U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Visualizations Tool, based on 2020 submission data (1999-2018). U.S. Department of Health and Human Services, Cancers for Disease Control and Prevention and National Cancer Institute. https://gis​.cdc.gov/Cancer​/USCS/#/AtAGlance/ Updated June 2021. Accessed May 22, 2022.
10.
SEER Explorer. Breast Cancer: SEER 5-year Age-Adjusted Incidence Rates, 2015-2019. National Institutes of Health and National Cancer Institute. https://seer​.cancer.gov​/explorer/application.html. Published 2022. Accessed February 16, 2023.
11.
National Cancer Institute (NCI) Surveillance Epidemiology and End Results (SEER) Program. Cancer Stat Facts: Female Breast Cancer. National Institutes of Health and National Cancer Institute. https://seer​.cancer.gov​/statfacts/html/breast.html. Published 2020. Accessed March 3, 2023.
12.
13.
U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data (1999-2017). Centers for Disease Control and Prevention and National Cancer Institute. www​.cdc.gov/cancer/dataviz. Published 2020. Updated June, 2020. Accessed September 24, 2020.
14.
Giaquinto AN, Sung H, Miller KD, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. [PubMed: 36190501]
15.
Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. 2022;128(24):4251–4284. [PMC free article: PMC10092838] [PubMed: 36301149]
16.
Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER Research Limited-Field Data with Delay-Adjustment, 22 Registries, Malignant Only, Nov 2021 Sub (2000-2019) - Linked To County Attributes - Time Dependent (1990-2019) Income/Rurality, 1969-2020 Counties. National Cancer Institute, DCCPS, Surveillance Research Program;Released April 2022, based on the November 2021 submission.
17.
Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in Cancer Incidence and Trends among American Indians and Alaska Natives in the United States, 2010-2015. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1604–1611. [PMC free article: PMC6777852] [PubMed: 31575554]
18.
Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–173. [PubMed: 25585328]
19.
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–451. [PubMed: 31577379]
20.
Jatoi I, Sung H, Jemal A. The Emergence of the Racial Disparity in U.S. Breast-Cancer Mortality. N Engl J Med. 2022;386(25):2349–2352. [PubMed: 35713541]
21.
American Association for Cancer Research. AACR Cancer Disparities Progress Report 2020. http://www​.CancerDisparitiesProgressReport.org. Published 2020. Accessed September 23, 2020.
22.
National Center for Health Statistics. Table 033: Use of mammography among women aged 40 and over, by selected characteristics: United States, selected years 1987–2015. Centers for Disease Control and Prevention. Health, United States, 2018 – Data Finder Web site. https://www​.cdc.gov/nchs​/hus/contents2018.htm#Table_033. Published 2019. Accessed Oct 27, 2020.
23.
SEER Explorer. Breast Cancer: U.S Mortality Rates by Age at Death, 2016-2020. National Institutes of Health and National Cancer Institute. https://seer​.cancer.gov​/explorer/application.html. Published 2022. Accessed February 16, 2023.
24.
SEER Explorer. Breast Cancer: SEER 5-Year Relative Survival Rates, 2012-2018. National Institutes of Health and National Cancer Institute. https://seer​.cancer.gov​/explorer/application.html. Published 2022. Accessed February 16, 2023.
25.
Rodgers KM, Udesky JO, Rudel RA, Brody JG. Environmental chemicals and breast cancer: An updated review of epidemiological literature informed by biological mechanisms. Environ Health.160:152–182. [PubMed: 28987728]
26.
National Cancer Institute. Breast Cancer and the Environment: Controversial and Emerging Exposures Workshop Summary. National Institutes of Health. https://www​.cancer.gov​/research/areas/causes​/breast-cancer-environment. Published 2021. Accessed June 2, 2022.
27.
Kresovich JK, Xu Z, O’Brien KM, Weinberg CR, Sandler DP, Taylor JA. Methylation-based biological age and breast cancer risk. Journal of the National Cancer Institute. 2019;111(10):1051–1058. [PMC free article: PMC6792078] [PubMed: 30794318]
28.
O’Brien KM, Sandler DP, Taylor JA, Weinberg CR. Serum vitamin D and risk of breast cancer within five years. Environ Health Perspect. 2017;125(7):077004. [PMC free article: PMC5744694] [PubMed: 28728134]
29.
Park YM, O’Brien KM, Zhao S, Weinberg CR, Baird DD, Sandler DP. Gestational diabetes mellitus may be associated with increased risk of breast cancer. Br J Cancer. 2017;116(7):960–963. [PMC free article: PMC5379146] [PubMed: 28208154]
30.
White AJ, Weinberg CR, Park YM, et al. Sleep characteristics, light at night and breast cancer risk in a prospective cohort. Int J Cancer. 2017;141(11):2204–2214. [PMC free article: PMC5633507] [PubMed: 28791684]
31.
Lawson JS, Günzburg WH, Whitaker NJ. Viruses and human breast cancer. Future Microbiol. 2006;1(1):33–51. [PubMed: 17661684]
32.
American Cancer Society. Breast Cancer Facts & Figures 2019-2020. American Cancer Society, Inc. https://www​.cancer.org​/content/dam/cancer-org​/research/cancer-facts-and-statistics​/breast-cancer-facts-and-figures​/breast-cancer-facts-and-figures-2019-2020.pdf. Published 2019. Accessed March 8, 2023.
33.
National Comprehensive Cancer Network. NCCN Guidelines: Breast Cancer Screening and Diagnosis. https://www​.nccn.org​/guidelines/nccn-guidelines​/guidelines-detail?category​=2&id=1421. Published 2022. Accessed March 10, 2023.
34.
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update. J Clin Oncol. 2020;38(12):1346–1366. [PubMed: 31928404]
35.
Zhu X, Chen L, Huang B, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10(1):225. [PMC free article: PMC6959292] [PubMed: 31937819]
36.
Plevritis SK, Munoz D, Kurian AW, et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA. 2018;319(2):154–164. [PMC free article: PMC5833658] [PubMed: 29318276]
37.
Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Female Breast Cancer Subtypes. National Institutes of Health and National Cancer Institute. https://seer​.cancer.gov​/statfacts/html/breast.html. Published 2020. Accessed March 3, 2023.
38.
Howlader N, Cronin KA, Kurian AW, Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–626. [PubMed: 29593010]
39.
Evans A, Pinder S, Wilson R, et al. Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. AJR Am J Roentgenol. 1994;162(6):1307–1311. [PubMed: 8191988]
40.
Neal CH, Joe AI, Patterson SK, Pujara AC, Helvie MA. Digital Mammography Has Persistently Increased High-Grade and Overall DCIS Detection Without Altering Upgrade Rate. AJR Am J Roentgenol. 2021;216(4):912–918. [PubMed: 33594910]
41.
Erbas B, Provenzano E, Armes J, Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135–144. [PubMed: 16319971]
42.
Chootipongchaivat S, van Ravesteyn NT, Li X, et al. Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Res. 2020;22(1):53. [PMC free article: PMC7251719] [PubMed: 32460821]
43.
Gorringe KL, Fox SB. Ductal carcinoma in situ biology, biomarkers, and diagnosis. Front Oncol. 2017;7:248. [PMC free article: PMC5660056] [PubMed: 29109942]
44.
Giannakeas V, Sopik V, Narod SA. Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. JAMA Netw Open. 2020;3(9):e2017124. [PMC free article: PMC7495235] [PubMed: 32936299]
45.
Hwang ES, Miglioretti DL, Ballard-Barbash R, Weaver DL, Kerlikowske K. Association between breast density and subsequent breast cancer following treatment for ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2587–2593. [PubMed: 18086762]
46.
Allegra CJ, Aberle DR, Ganschow P, et al. NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS). NIH Consens State Sci Statements. 2009;26(2):1–27. [PubMed: 19784089]
47.
Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol Biomarkers Prev. 2019;28(5):835–845. [PubMed: 31023696]
48.
Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019;322(7):666–685. [PubMed: 31429902]
49.
Owens DK, Davidson KW, Krist AH, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322(7):652–665. [PubMed: 31429903]
50.
Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156(9):635–648. [PMC free article: PMC3561467] [PubMed: 22547473]
51.
Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358(9291):1389–1399. [PubMed: 11705483]
52.
Braithwaite D, Miglioretti DL, Zhu W, et al. Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA internal medicine. 2018;178(4):494–501. [PMC free article: PMC5876845] [PubMed: 29435563]
53.
McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159–1169. [PubMed: 16775176]
54.
National Cancer Institute. Breast Cancer Prevention (PDQ®)–Health Professional Version 06/10/2022. National Cancer Institute. https://www​.cancer.gov​/types/breast/hp/breast-screening-pdq#section/all. Published 2018. Accessed August 27, 2022.
55.
D’Orsi C, Sickles E, Mendelson E, Morris E. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
56.
Melnikow J, Fenton J, DL M, Whitlock E, Weyrich M. Screening for Breast Cancer with Digital Breast Tomosynthesis In: Rockville, MD: Agency for Healthcare Research and Quality; 2016. [PubMed: 26866207]
57.
Sprague BL, Gangnon RE, Burt V, et al. Prevalence of mammographically dense breasts in the United States. Journal of the National Cancer Institute. 2014;106(10). [PMC free article: PMC4200066] [PubMed: 25217577]
58.
Advani SM, Zhu W, Demb J, et al. Association of breast density with breast cancer risk among women aged 65 years or older by age group and body mass index. JAMA Netw Open. 2021;4(8):e2122810–e2122810. [PMC free article: PMC8391100] [PubMed: 34436608]
59.
Bissell MCS, Kerlikowske K, Sprague BL, et al. Breast cancer population attributable risk proportions associated with body mass index and breast density by race/ethnicity and menopausal status. Cancer Epidemiol Biomarkers Prev. 2020;29(10):2048–2056. [PMC free article: PMC7541499] [PubMed: 32727722]
60.
Mokhtary A, Karakatsanis A, Valachis A. Mammographic density changes over time and breast cancer risk: a systematic review and meta-analysis. Cancers (Basel). 2021;13(19):4805. [PMC free article: PMC8507818] [PubMed: 34638289]
61.
Burton A, Maskarinec G, Perez-Gomez B, et al. Mammographic density and ageing: A collaborative pooled analysis of cross-sectional data from 22 countries worldwide. PLoS Med. 2017;14(6):e1002335. [PMC free article: PMC5493289] [PubMed: 28666001]
62.
National Cancer Institute. Dense Breasts: Answers to Commonly Asked Questions. National Institutes of Health. https://www​.cancer.gov​/types/breast/breast-changes​/dense-breasts. Published 2020. Accessed September 25, 2020.
63.
Kerlikowske K, Sprague BL, Tosteson ANA, et al. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging. JAMA internal medicine. 2019;[Epub ahead of print]. [PMC free article: PMC6604099] [PubMed: 31260054]
64.
Sprague BL, Kerlikowske K, Bowles EJA, et al. Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium. Journal of the National Cancer Institute. 2019. [PMC free article: PMC6579740] [PubMed: 30624682]
65.
Azam S, Sjölander A, Eriksson M, Gabrielson M, Czene K, Hall P. Determinants of Mammographic Density Change. JNCI Cancer Spectr. 2019;3(1):pkz004–pkz004. [PMC free article: PMC6649843] [PubMed: 31360892]
66.
Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute. 1989;81(24):1879–1886. [PubMed: 2593165]
67.
Claus EB, Risch N, Thompson WD. The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Res Treat. 1993;28(2):115–120. [PubMed: 8173064]
68.
Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148(5):337–347. [PMC free article: PMC2674327] [PubMed: 18316752]
69.
Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction modelincorporating genetic and nongenetic risk factors. Genet Med. 2019;21(8):1708–1718. [PMC free article: PMC6687499] [PubMed: 30643217]
70.
Euhus DM, Smith KC, Robinson L, et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. Journal of the National Cancer Institute. 2002;94(11):844–851. [PubMed: 12048272]
71.
Maas P, Barrdahl M, Joshi AD, et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. JAMA Oncol. 2016;2(10):1295–1302. [PMC free article: PMC5719876] [PubMed: 27228256]
72.
Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019;322(9):868–886. [PubMed: 31479143]
73.
Louro J, Posso M, Hilton Boon M, et al. A systematic review and quality assessment of individualised breast cancer risk prediction models. Br J Cancer. 2019;121(1):76–85. [PMC free article: PMC6738106] [PubMed: 31114019]
74.
Yanes T, Young M-A, Meiser B, James PA. Clinical applications of polygenic breast cancer risk: a critical review and perspectives of an emerging field. Breast Cancer Res. 2020;22(1):21. [PMC free article: PMC7026946] [PubMed: 32066492]
75.
Nelson HD, Tyne K, Naik A, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Screening for Breast Cancer: Systematic Evidence Review Update for the US Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009. [PubMed: 20722173]
76.
Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of Breast Cancer Screening: Systematic Review and Meta-analysis to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016;164(4):244–255. [PubMed: 26756588]
77.
Duffy SW, Vulkan D, Cuckle H, et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancel Oncol. 2020;21(9):1165–1172. [PMC free article: PMC7491203] [PubMed: 32800099]
78.
Duffy S, Vulkan D, Cuckle H, et al. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. Health Technol Assess. 2020;24(55):1–24. [PMC free article: PMC7681269] [PubMed: 33141657]
79.
Johnson K, Lang K, Ikeda DM, Akesson A, Andersson I, Zackrisson S. Interval Breast Cancer Rates and Tumor Characteristics in the Prospective Population-based Malmo Breast Tomosynthesis Screening Trial. Radiology. 2021;299(3):559–567. [PubMed: 33825509]
80.
Johnson K, Zackrisson S, Rosso A, et al. Tumor Characteristics and Molecular Subtypes in Breast Cancer Screening with Digital Breast Tomosynthesis: the Malmö Breast Tomosynthesis Screening Trial. Radiology. 2019;293(2):273–281. [PubMed: 31478799]
81.
Canelo-Aybar C, Posso M, Montero N, et al. Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC). Br J Cancer. 2022;126(4):673–688. [PMC free article: PMC8854566] [PubMed: 34837076]
82.
Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study. Lancel Oncol. 2013;14(7):583–589. [PubMed: 23623721]
83.
Skaane P, Bandos AI, Eben EB, et al. Two-View Digital Breast Tomosynthesis Screening with Synthetically Reconstructed Projection Images: Comparison with Digital Breast Tomosynthesis with Full-Field Digital Mammographic Images. Radiology. 2014;271(3):655–663. [PubMed: 24484063]
84.
Durand MA. Synthesized Mammography: Clinical Evidence, Appearance, and Implementation. Diagnostics (Basel). 2018;8(2):04. [PMC free article: PMC6023509] [PubMed: 29617294]
85.
Abdullah P, Alabousi M, Ramadan S, et al. Synthetic 2D Mammography Versus Standard 2D Digital Mammography: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2021;217(2):314–325. [PubMed: 32966115]
86.
Alabousi M, Wadera A, Kashif Al-Ghita M, et al. Performance of Digital Breast Tomosynthesis, Synthetic Mammography, and Digital Mammography in Breast Cancer Screening: A Systematic Review and Meta-Analysis. J Natl Cancer Cent. 2021;113(6):680–690. [PMC free article: PMC8168096] [PubMed: 33372954]
87.
Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med. 2016;375(15):1438–1447. [PubMed: 27732805]
88.
Davies L, Petitti DB, Woo M, Lin JS. Defining, Estimating, and Communicating Overdiagnosis in Cancer Screening. Ann Intern Med. 2018;169(11):824. [PubMed: 30508437]
89.
Miglioretti DL, Lange J, van den Broek JJ, et al. Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med. 2016;164(4):205–214. [PMC free article: PMC4878445] [PubMed: 26756460]
90.
Ma AK, Darambara DG, Stewart A, Gunn S, Bullard E. Mean glandular dose estimation using MCNPX for a digital breast tomosynthesis system with tungsten/aluminum and tungsten/aluminum+silver x-ray anode-filter combinations. Med Phys. 2008;35(12):5278–5289. [PubMed: 19175087]
91.
Pattacini P, Nitrosi A, Giorgi Rossi P, et al. Digital Mammography versus Digital Mammography Plus Tomosynthesis for Breast Cancer Screening: The Reggio Emilia Tomosynthesis Randomized Trial. Radiology. 2018;288(2):375–385. [PubMed: 29869961]
92.
Niklason LT, Christian BT, Niklason LE, et al. Digital tomosynthesis in breast imaging. Radiology. 1997;205(2):399–406. [PubMed: 9356620]
93.
Niklason LT, Kopans DB, Hamberg LM. Digital breast imaging: tomosynthesis and digital subtraction mammography. Breast Dis. 1998;10(3–4):151–164. [PubMed: 15687571]
94.
Caumo F, Romanucci G, Hunter K, et al. Comparison of breast cancers detected in the Verona screening program following transition to digital breast tomosynthesis screening with cancers detected at digital mammography screening. Breast Cancer Res Treat. 2018;20:20. [PubMed: 29557996]
95.
Melnikow J, Fenton JJ, Whitlock EP, et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. In: Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Service Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); January 2016. [PubMed: 26866210]
96.
Yankaskas BC, Klabunde CN, Ancelle-Park R, et al. International comparison of performance measures for screening mammography: can it be done? J Med Screen. 2004;11(4):187–193. [PubMed: 15624239]
97.
Thurfjell EL, Lernevall KA, Taube AA. Benefit of independent double reading in a population-based mammography screening program. Radiology. 1994;191(1):241–244. [PubMed: 8134580]
98.
Azavedo E, Zackrisson S, Mejàre I, Heibert Arnlind M. Is single reading with computer-aided detection (CAD) as good as double reading in mammography screening? A systematic review. BMC Med Imaging. 2012;12:22. [PMC free article: PMC3464719] [PubMed: 22827803]
99.
Taylor P, Potts HW. Computer aids and human second reading as interventions in screening mammography: two systematic reviews to compare effects on cancer detection and recall rate. Eur J Cancer. 2008;44(6):798–807. [PubMed: 18353630]
100.
Bennett RL, Blanks RG, Moss SM. Does the accuracy of single reading with CAD (computer-aided detection) compare with that of double reading?: A review of the literature. Clin Radiol. 2006;61(12):1023–1028. [PubMed: 17097423]
101.
Richman IB, Hoag JR, Xu X, et al. Adoption of Digital Breast Tomosynthesis in Clinical Practice. JAMA internal medicine. 2019;179(9):1292–1295. [PMC free article: PMC6593646] [PubMed: 31233086]
102.
Mammography Quality Standards Act and Program (MQSA). MQSA National Statistics. https://www​.fda.gov/radiation-emitting-products​/mqsa-insights​/mqsa-national-statistics. Published December 2020. Accessed December 10, 2020.
103.
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. [PubMed: 30667505]
104.
Czajka M, Pfeifer C. Breast Cancer Surgery. In: StatPearls. Treasure Island (FL): StatPearls Publishing: https://www​.ncbi.nlm​.nih.gov/books/NBK553076/. [PubMed: 31971717]
105.
American Cancer Society. Breast Biopsy. https://www​.cancer.org​/cancer/breast-cancer​/screening-tests-and-early-detection​/breast-biopsy.html. Published 2019. Accessed October 27, 2020.
106.
Amin MB, Edge SB, Greene F, JD. B. AJCC cancer staging manual, 8th Edition. . 2017.
107.
Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303. [PubMed: 28294295]
108.
Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol. 2008;15(7):1996–2005. [PubMed: 18415650]
109.
Chen JC, Li Y, Fisher JL, Bhattacharyya O, Tsung A, Obeng-Gyasi S. Neighborhood socioeconomic status and low-value breast cancer care. J Surg Oncol. 2022;126(3):433–442. [PMC free article: PMC9541043] [PubMed: 35452136]
110.
Nayyar A, Strassle PD, Schlottmann F, et al. Disparities in the Use of Sentinel Lymph Node Dissection for Early Stage Breast Cancer. J Surg Res. 2020;254:31–40. [PubMed: 32408028]
111.
Nelson HD, Cantor A, Humphrey L, et al. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. 01 2016. [PubMed: 26889531]
112.
U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. Rockville, MD: U.S. Preventive Services Task Force; 2023.
113.
Wang S, Sultana F, Kavanagh A, et al. Benefits and harms of breast cancer screening: Cohort study of breast cancer mortality and overdiagnosis. Cancer Med. 2023;12(17):18120–18132. [PMC free article: PMC10524083] [PubMed: 37548277]
114.
Richman IB, Long JB, Soulos PR, Wang SY, Gross CP. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Ann Intern Med. 2023;176(9):1172–1180. [PMC free article: PMC10623662] [PubMed: 37549389]
115.
Caughey AB, Krist AH, Wolff TA, et al. USPSTF Approach to Addressing Sex and Gender When Making Recommendations for Clinical Preventive Services. JAMA. 2021;326(19):1953–1961. [PubMed: 34694343]
116.
United Nations Development Programme. 2020 Statistical Update: Human Development Indices and Indicators. New York2020.
117.
Hellquist BN, Duffy SW, Abdsaleh S, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2011;117(4):714–722. [PubMed: 20882563]
118.
Mao Z, Nystrom L, Jonsson H. Effectiveness of Population-Based Service Screening with Mammography for Women Aged 70-74 Years in Sweden. Cancer Epidemiol Biomarkers Prev. 2020;29(11):2149–2156. [PubMed: 32856607]
119.
Seely JM, Peddle SE, Yang H, et al. Breast Density and Risk of Interval Cancers: The Effect of Annual Versus Biennial Screening Mammography Policies in Canada. Can Assoc Radiol J. 2021:8465371211027958. [PubMed: 34279132]
120.
Castellano CR, Aguilar Angulo PM, Hernandez LC, et al. Breast cancer mortality after eight years of an improved screening program using digital breast tomosynthesis. J Med Screen. 2021:9691413211002556. [PMC free article: PMC8573629] [PubMed: 33775181]
121.
Canelo-Aybar C, Carrera L, Beltran J, et al. Digital breast tomosynthesis compared to diagnostic mammographic projections (including magnification) among women recalled at screening mammography: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC). Cancer Med. 2021;10(7):2191–2204. [PMC free article: PMC7982617] [PubMed: 33675147]
122.
Ryser MD, Lange J, Inoue LYT, et al. Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. Ann Intern Med. 2022;175(4):471–478. [PMC free article: PMC9359467] [PubMed: 35226520]
123.
Dunn BK, Woloshin S, Xie H, Kramer BS. Cancer overdiagnosis: A challenge in the era of screening. J Natl Cancer Cent. 2022;2(4):235–242. [PMC free article: PMC9784987] [PubMed: 36568283]
124.
van Ravesteyn NT, van den Broek JJ, Li X, et al. Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Med Decis Making. 2018;38(1_suppl):126S–139S. [PMC free article: PMC5862063] [PubMed: 29554463]
125.
Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394. [PubMed: 21195583]
126.
The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research. Eur J Cancer. 2002;38(11):1458–1464. [PubMed: 12110490]
127.
Aase HS, Danielsen AS, Hoff SR, et al. Mammographic features and screening outcome in a randomized controlled trial comparing digital breast tomosynthesis and digital mammography. Eur J Radiol. 2021;141:109753. [PubMed: 34053786]
128.
Aase HS, Holen AS, Pedersen K, et al. A randomized controlled trial of digital breast tomosynthesis versus digital mammography in population-based screening in Bergen: interim analysis of performance indicators from the To-Be trial. Eur Radiol. 2019;29(3):1175–1186. [PMC free article: PMC6510877] [PubMed: 30159620]
129.
Armaroli P, Frigerio A, Correale L, et al. A randomised controlled trial of Digital Breast Tomosynthesis versus Digital Mammography as primary screening tests: screening results over subsequent episodes of the Proteus Donna study. Int J Cancer. 2022;151(10):1778–1790. [PubMed: 35689673]
130.
Bakker MF, de Lange SV, Pijnappel RM, et al. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med. 2019;381(22):2091–2102. [PubMed: 31774954]
131.
Braithwaite D, Zhu W, Hubbard RA, et al. Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? Journal of the National Cancer Institute. 2013;105(5):334–341. [PMC free article: PMC3589257] [PubMed: 23385442]
132.
Conant EF, Beaber EF, Sprague BL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography compared to digital mammography alone: a cohort study within the PROSPR consortium. Breast Cancer Res Treat. 2016;156(1):109–116. [PMC free article: PMC5536249] [PubMed: 26931450]
133.
de Lange SV, Bakker MF, Monninkhof EM, et al. Reasons for (non)participation in supplemental population-based MRI breast screening for women with extremely dense breasts. Clin Radiol. 2018;73(8):759.e751–759.e759. [PubMed: 29759590]
134.
Dittus K, Geller B, Weaver DL, et al. Impact of mammography screening interval on breast cancer diagnosis by menopausal status and BMI. J Gen Intern Med. 2013;28(11):1454–1462. [PMC free article: PMC3797353] [PubMed: 23760741]
135.
Ganguli I, Keating NL, Thakore N, Lii J, Raza S, Pace LE. Downstream Mammary and Extramammary Cascade Services and Spending Following Screening Breast Magnetic Resonance Imaging vs Mammography Among Commercially Insured Women. JAMA Netw Open. 2022;5(4):e227234. [PMC free article: PMC9008498] [PubMed: 35416989]
136.
Garcia-Albeniz X, Hernan MA, Logan RW, Price M, Armstrong K, Hsu J. Continuation of Annual Screening Mammography and Breast Cancer Mortality in Women Older Than 70 Years. Ann Intern Med. 2020;172(6):381–389. [PubMed: 32092767]
137.
Goel A, Littenberg B, Burack RC. The association between the pre-diagnosis mammography screening interval and advanced breast cancer. Breast Cancer Res Treat. 2007;102(3):339–345. [PMC free article: PMC1839955] [PubMed: 16927175]
138.
Harada-Shoji N, Suzuki A, Ishida T, et al. Evaluation of Adjunctive Ultrasonography for Breast Cancer Detection Among Women Aged 40-49 Years With Varying Breast Density Undergoing Screening Mammography: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021;4(8):e2121505. [PMC free article: PMC8374606] [PubMed: 34406400]
139.
Heindel W, Weigel S, Gerß J, et al. Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Oncol. 2022;23(5):601–611. [PubMed: 35427470]
140.
Ho TH, Bissell MCS, Kerlikowske K, et al. Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. JAMA Netw Open. 2022;5(3):e222440. [PMC free article: PMC8956976] [PubMed: 35333365]
141.
Hofvind S, Holen AS, Aase HS, et al. Two-view digital breast tomosynthesis versus digital mammography in a population-based breast cancer screening programme (To-Be): a randomised, controlled trial. Lancel Oncol. 2019;20(6):795–805. [PubMed: 31078459]
142.
Hofvind S, Hovda T, Holen AS, et al. Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Digital Mammography: Evaluation in a Population-based Screening Program. Radiology. 2018;287(3):787–794. [PubMed: 29494322]
143.
Hofvind S, Moshina N, Holen AS, et al. Interval and Subsequent Round Breast Cancer in a Randomized Controlled Trial Comparing Digital Breast Tomosynthesis and Digital Mammography Screening. Radiology. 2021;300(1):66–76. [PubMed: 33973840]
144.
Hovda T, Holen AS, Lang K, et al. Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway. Radiology. 2020;294(2):256–264. [PubMed: 31821118]
145.
Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011;155(8):481–492. [PMC free article: PMC3209800] [PubMed: 22007042]
146.
Ishida T, Suzuki A, Kawai M, et al. A randomized controlled trial to verify the efficacy of the use of ultrasonography in breast cancer screening aged 40-49 (J-START): 76 196 women registered. Jpn J Clin Oncol. 2014;44(2):134–140. [PubMed: 24407835]
147.
Kerlikowske K, Su Y-R, Sprague BL, et al. Association of Screening With Digital Breast Tomosynthesis vs Digital Mammography With Risk of Interval Invasive and Advanced Breast Cancer. JAMA. 2022;327(22):2220–2230. [PMC free article: PMC9198754] [PubMed: 35699706]
148.
Kerlikowske K, Zhu W, Hubbard RA, et al. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA internal medicine. 2013;173(9):807–816. [PMC free article: PMC3699693] [PubMed: 23552817]
149.
Klemi PJ, Toikkanen S, Räsänen O, Parvinen I, Joensuu H. Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer. 1997;75(5):762–766. [PMC free article: PMC2063348] [PubMed: 9043038]
150.
Lang K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S. Performance of one-view breast tomosynthesis as a stand-alone breast cancer screening modality: results from the Malmo Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol. 2016;26(1):184–190. [PMC free article: PMC4666282] [PubMed: 25929946]
151.
Lang K, Nergarden M, Andersson I, Rosso A, Zackrisson S. False positives in breast cancer screening with one-view breast tomosynthesis: An analysis of findings leading to recall, work-up and biopsy rates in the Malmo Breast Tomosynthesis Screening Trial. Eur Radiol. 2016;26(11):3899–3907. [PMC free article: PMC5052302] [PubMed: 26943342]
152.
Lee JM, Arao RF, Sprague BL, et al. Performance of Screening Ultrasonography as an Adjunct to Screening Mammography in Women Across the Spectrum of Breast Cancer Risk. JAMA internal medicine. 2019;179(5):658–667. [PMC free article: PMC6503561] [PubMed: 30882843]
153.
McGuinness JE, Ueng W, Trivedi MS, et al. Factors Associated with False Positive Results on Screening Mammography in a Population of Predominantly Hispanic Women. Cancer Epidemiol Biomarkers Prev. 2018;27(4):446–453. [PMC free article: PMC5884721] [PubMed: 29382701]
154.
Miglioretti DL, Zhu W, Kerlikowske K, et al. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status. JAMA Oncol. 2015;1(8):1069–1077. [PMC free article: PMC4644100] [PubMed: 26501844]
155.
Moger TA, Swanson JO, Holen AS, Hanestad B, Hofvind S. Cost differences between digital tomosynthesis and standard digital mammography in a breast cancer screening programme: results from the To-Be trial in Norway. Eur J Health Econ. 2019;20(8):1261–1269. [PMC free article: PMC6803617] [PubMed: 31399773]
156.
Moshina N, Aase HS, Danielsen AS, et al. Comparing Screening Outcomes for Digital Breast Tomosynthesis and Digital Mammography by Automated Breast Density in a Randomized Controlled Trial: Results from the To-Be Trial. Radiology. 2020;297(3):522–531. [PubMed: 32930649]
157.
Nelson HD, O’Meara ES, Kerlikowske K, Balch S, Miglioretti D. Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data. Ann Intern Med. 2016;164(4):226–235. [PMC free article: PMC5091936] [PubMed: 26756902]
158.
Ohuchi N, Suzuki A, Sobue T, et al. Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan Strategic Anti-cancer Randomized Trial (J-START): a randomised controlled trial. Lancet. 2016;387(10016):341–348. [PubMed: 26547101]
159.
Parvinen I, Chiu S, Pylkkänen L, et al. Effects of annual vs triennial mammography interval on breast cancer incidence and mortality in ages 40-49 in Finland. Br J Cancer. 2011;105(9):1388–1391. [PMC free article: PMC3241549] [PubMed: 21934688]
160.
Pattacini P, Nitrosi A, Giorgi Rossi P, et al. A Randomized Trial Comparing Breast Cancer Incidence and Interval Cancers after Tomosynthesis Plus Mammography versus Mammography Alone. Radiology. 2022:211132. [PubMed: 35103537]
161.
Pattacini P, Nitrosi A, Giorgi Rossi P, et al. Digital Mammography versus Digital Mammography Plus Tomosynthesis for Breast Cancer Screening: The Reggio Emilia Tomosynthesis Randomized Trial. Radiology. 2018;288(2):375–385. [PubMed: 29869961]
162.
Richman IB, Long JB, Hoag JR, et al. Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old. J Natl Cancer Cent. 2021;03:03. [PMC free article: PMC8757313] [PubMed: 33822120]
163.
Rosso A, Lang K, Petersson IF, Zackrisson S. Factors affecting recall rate and false positive fraction in breast cancer screening with breast tomosynthesis - A statistical approach. Breast. 2015;24(5):680–686. [PubMed: 26365133]
164.
Veenhuizen SGA, de Lange SV, Bakker MF, et al. Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial. Radiology. 2021;299(2):278–286. [PubMed: 33724062]
165.
Waade G, Holen Å, Sebuødegård S, et al. Breast compression parameters among women screened with standard digital mammography and digital breast tomosynthesis in a randomized controlled trial. Acta Radiol. 2020;61(3):321–330. [PubMed: 31342757]
166.
White E, Miglioretti DL, Yankaskas BC, et al. Biennial versus annual mammography and the risk of late-stage breast cancer. Journal of the National Cancer Institute. 2004;96(24):1832–1839. [PubMed: 15601639]
167.
Zackrisson S, Lang K, Rosso A, et al. One-view breast tomosynthesis versus two-view mammography in the Malmo Breast Tomosynthesis Screening Trial (MBTST): a prospective, population-based, diagnostic accuracy study. Lancel Oncol. 2018;19(11):1493–1503. [PubMed: 30322817]
168.
Sprague B, Coley RY, Lowry K, et al. Digital breast tomosynthesis versus digital mammography screening performance on successive screening rounds from the Breast Cancer Surveillance Consortium. Radiology 2023;307(5):e223142. [PMC free article: PMC10315524] [PubMed: 37249433]
169.
Hernán MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183(8):758–764. [PMC free article: PMC4832051] [PubMed: 26994063]
170.
Acerbi I, Fiscalini A, Che M, et al. Personalized breast cancer screening in a population-based study: women informed to screen depending on measures of risk (WISDOM). Cancer Res. 2021;81(4 suppl).
171.
Doubovetzky J, Bour C. Use of screening research to boost overdiagnosis: the mypebs trial. BMJ Evid Based Med. 2019;24:A43-.
172.
García-Albéniz X, Hsu J, Bretthauer M, Hernán MA. Effectiveness of Screening Colonoscopy to Prevent Colorectal Cancer Among Medicare Beneficiaries Aged 70 to 79 Years: A Prospective Observational Study. Ann Intern Med. 2017;166(1):18–26. [PMC free article: PMC5417337] [PubMed: 27669524]
173.
Cook AJ, Elmore JG, Miglioretti DL, et al. Decreased accuracy in interpretation of community-based screening mammography for women with multiple clinical risk factors. J Clin Epidemiol. 2010;63(4):441–451. [PMC free article: PMC2837135] [PubMed: 19744825]
174.
Nelson HD. Mammography Screening and Overdiagnosis. JAMA Oncol. 2016;2(2):261–262. [PubMed: 26501939]
175.
Heywang-Köbrunner S-H, Jänsch A, Hacker A, Weinand S, Vogelmann T. Tomosynthesis with synthesised two-dimensional mammography yields higher cancer detection compared to digital mammography alone, also in dense breasts and in younger women: A systematic review and meta-analysis. Eur J Radiol. 2022;152. [PubMed: 35576720]
176.
Libesman S, Zackrisson S, Hofvind S, et al. An individual participant data meta-analysis of breast cancer detection and recall rates for digital breast tomosynthesis versus digital mammography population screening. Clin Breast Cancer. 2022;22(5):e647–e654. [PubMed: 35246389]
177.
Giampietro RR, Cabral MVG, Lima SAM, Weber SAT, Dos Santos Nunes-Nogueira V. Accuracy and Effectiveness of Mammography versus Mammography and Tomosynthesis for Population-Based Breast Cancer Screening: A Systematic Review and Meta-Analysis. Sci Rep. 2020;10(1):7991. [PMC free article: PMC7224282] [PubMed: 32409756]
178.
Lowry KP, Coley RY, Miglioretti DL, et al. Screening Performance of Digital Breast Tomosynthesis vs Digital Mammography in Community Practice by Patient Age, Screening Round, and Breast Density. JAMA Netw Open. 2020;3(7):e2011792–e2011792. [PMC free article: PMC7388021] [PubMed: 32721031]
179.
Mizzi D, Allely C, Zarb F, et al. Examining the effectiveness of supplementary imaging modalities for breast cancer screening in women with dense breasts: A systematic review and meta-analysis. Eur J Radiol. 2022;154:110416. [PubMed: 35803102]
180.
Yuan WH, Hsu HC, Chen YY, Wu CH. Supplemental breast cancer-screening ultrasonography in women with dense breasts: a systematic review and meta-analysis. Br J Cancer. 2020;123(4):673–688. [PMC free article: PMC7434777] [PubMed: 32528118]
181.
Yang L, Wang S, Zhang L, et al. Performance of ultrasonography screening for breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20(1):499. [PMC free article: PMC7268243] [PubMed: 32487106]
182.
Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. Journal of the National Cancer Institute. 2017;109(9). [PMC free article: PMC5409140] [PubMed: 28376154]
183.
Lewis-Thames MW, Langston ME, Khan S, et al. Racial and Ethnic Differences in Rural-Urban Trends in 5-Year Survival of Patients With Lung, Prostate, Breast, and Colorectal Cancers: 1975-2011 Surveillance, Epidemiology, and End Results (SEER). JAMA Netw Open. 2022;5(5):e2212246–e2212246. [PMC free article: PMC9121191] [PubMed: 35587350]
184.
Alvidrez J, Castille D, Laude-Sharp M, Rosario A, Tabor D. The National Institute on Minority Health and Health Disparities Research Framework. Am J Public Health. 2019;109(S1):S16–s20. [PMC free article: PMC6356129] [PubMed: 30699025]
185.
Nong P, Raj M, Creary M, Kardia SLR, Platt JE. Patient-Reported Experiences of Discrimination in the US Health Care System. JAMA Netw Open. 2020;3(12):e2029650. [PMC free article: PMC7739133] [PubMed: 33320264]
186.
Nelson HD, Cantor A, Wagner J, et al. Effectiveness of Patient Navigation to Increase Cancer Screening in Populations Adversely Affected by Health Disparities: a Meta-analysis. J Gen Intern Med. 2020;35(10):3026–3035. [PMC free article: PMC7573022] [PubMed: 32700218]
187.
Williams DR, Priest N, Anderson NB. Understanding associations among race, socioeconomic status, and health: Patterns and prospects. Health Psychol. 2016;35(4):407–411. [PMC free article: PMC4817358] [PubMed: 27018733]
188.
Bailey ZD, Krieger N, Agénor M, Graves J, Linos N, Bassett MT. Structural racism and health inequities in the USA: evidence and interventions. Lancet. 2017;389(10077):1453–1463. [PubMed: 28402827]
189.
Zavala VA, Bracci PM, Carethers JM, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2020;124(2):315–332. [PMC free article: PMC7852513] [PubMed: 32901135]
190.
Bemanian A, Beyer KM. Measures Matter: The Local Exposure/Isolation (LEx/Is) Metrics and Relationships between Local-Level Segregation and Breast Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2017;26(4):516–524. [PMC free article: PMC5380473] [PubMed: 28325737]
191.
Collin LJ, Gaglioti AH, Beyer KM, et al. Neighborhood-Level Redlining and Lending Bias Are Associated with Breast Cancer Mortality in a Large and Diverse Metropolitan Area. Cancer Epidemiol Biomarkers Prev. 2021;30(1):53–60. [PMC free article: PMC7855192] [PubMed: 33008873]
192.
Goel N, Westrick AC, Bailey ZD, et al. Structural Racism and Breast Cancer-specific Survival: Impact of Economic and Racial Residential Segregation. Ann Surg. 2022;275(4):776–783. [PMC free article: PMC9102835] [PubMed: 35081560]
193.
Siegel SD, Brooks MM, Lynch SM, Sims-Mourtada J, Schug ZT, Curriero FC. Racial disparities in triple negative breast cancer: toward a causal architecture approach. Breast Cancer Res. 2022;24(1):37. [PMC free article: PMC9158353] [PubMed: 35650633]
194.
Kerlikowske K, Chen S, Golmakani MK, et al. Cumulative advanced breast cancer risk prediction model developed in a screening mammography population. Journal of the National Cancer Institute. 2022;114(5):676–685. [PMC free article: PMC9086807] [PubMed: 35026019]
195.
Niraula S, Biswanger N, Hu P, Lambert P, Decker K. Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers. JAMA Netw Open. 2020;3(9):e2018179. [PMC free article: PMC7519419] [PubMed: 32975573]
196.
Davis Lynn BC, Chernyavskiy P, Gierach GL, Rosenberg PS. Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region. Journal of the National Cancer Institute. 2022;114(2):263–270. [PMC free article: PMC8826530] [PubMed: 34508608]
197.
Nelson HD, Cantor A, Wagner J, et al. Achieving Health Equity in Preventive Services: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2020;172(4):258–271. [PubMed: 31931527]
198.
Centers for Disease Control and Prevention. BRFSS Web Enabled Analysis Tool. https://nccd​.cdc.gov/weat/#/analysis. Accessed August 29, 2022.
199.
Gorina Y, Elgaddal N. Patterns of Mammography, Pap Smear, and Colorectal Cancer Screening Services Among Women Aged 45 and Over. Natl Health Stat Report. 2021(157):1–18. [PubMed: 34181518]
200.
Lee CI, Lehman CD. Digital breast tomosynthesis and the challenges of implementing an emerging breast cancer screening technology into clinical practice. J Am Coll Radiol. 2013;10(12):913–917. [PubMed: 24295940]
201.
Lee CI, Zhu W, Onega T, et al. Comparative Access to and Use of Digital Breast Tomosynthesis Screening by Women’s Race/Ethnicity and Socioeconomic Status. JAMA Netw Open. 2021;4(2):e2037546. [PMC free article: PMC7896194] [PubMed: 33606032]
202.
Clark CR, Tosteson TD, Tosteson ANA, et al. Diffusion of digital breast tomosynthesis among women in primary care: associations with insurance type. Cancer Med. 2017;6(5):1102–1107. [PMC free article: PMC5430135] [PubMed: 28378409]
203.
Schifferdecker KE, Tosteson ANA, Kaplan C, et al. Knowledge and Perception of Breast Density, Screening Mammography, and Supplemental Screening: in Search of “Informed”. J Gen Intern Med. 2020;35(6):1654–1660. [PMC free article: PMC7280373] [PubMed: 31792869]
204.
Warnecke RB, Campbell RT, Vijayasiri G, Barrett RE, Rauscher GH. Multilevel Examination of Health Disparity: The Role of Policy Implementation in Neighborhood Context, in Patient Resources, and in Healthcare Facilities on Later Stage of Breast Cancer Diagnosis. Cancer Epidemiol Biomarkers Prev. 2019;28(1):59–66. [PMC free article: PMC6324957] [PubMed: 30352817]
205.
Onega T, Hubbard R, Hill D, et al. Geographic access to breast imaging for US women. J Am Coll Radiol. 2014;11(9):874–882. [PMC free article: PMC4156905] [PubMed: 24889479]
206.
Fayanju OM, Ren Y, Stashko I, et al. Patient-reported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis. Cancer. 2021;127(5):757–768. [PMC free article: PMC7897266] [PubMed: 33175437]
207.
Selove R, Kilbourne B, Fadden MK, et al. Time from Screening Mammography to Biopsy and from Biopsy to Breast Cancer Treatment among Black and White, Women Medicare Beneficiaries Not Participating in a Health Maintenance Organization. Womens Health Issues. 2016;26(6):642–647. [PMC free article: PMC5116399] [PubMed: 27773529]
208.
Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS. Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups. Cancer. 2017;123(18):3468–3475. [PMC free article: PMC5648644] [PubMed: 28603859]
209.
Warner ET, Tamimi RM, Hughes ME, et al. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 2012;136(3):813–821. [PMC free article: PMC3513497] [PubMed: 23099438]
210.
Kovar A, Bronsert M, Jaiswal K, et al. The Waiting Game: How Long Are Breast Cancer Patients Waiting for Definitive Diagnosis? Ann Surg Oncol. 2020;27(10):3641–3649. [PubMed: 32314153]
211.
Elmore JG, Nakano CY, Linden HM, Reisch LM, Ayanian JZ, Larson EB. Racial inequities in the timing of breast cancer detection, diagnosis, and initiation of treatment. Med Care. 2005;43(2):141–148. [PubMed: 15655427]
212.
Emerson MA, Golightly YM, Aiello AE, et al. Breast cancer treatment delays by socioeconomic and health care access latent classes in Black and White women. Cancer. 2020;126(22):4957–4966. [PMC free article: PMC7789230] [PubMed: 32954493]
213.
Lawson MB, Bissell MCS, Miglioretti DL, et al. Multilevel Factors Associated With Time to Biopsy After Abnormal Screening Mammography Results by Race and Ethnicity. JAMA Oncol. 2022;8(8):1115–1126. [PMC free article: PMC9227677] [PubMed: 35737381]
214.
Yussof I, Mohd Tahir NA, Hatah E, Mohamed Shah N. Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review. Breast. 2022;62:22–35. [PMC free article: PMC8818734] [PubMed: 35121501]
215.
Hu X, Walker MS, Stepanski E, et al. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer. JAMA Netw Open. 2022;5(8):e2225485. [PMC free article: PMC9366541] [PubMed: 35947386]
216.
Hu X, Chehal PK, Kaplan C, et al. Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer Before Starting Chemotherapy. JAMA Netw Open. 2021;4(6):e2112076. [PMC free article: PMC8170541] [PubMed: 34061200]
217.
Nystrom L, Bjurstam N, Jonsson H, Zackrisson S, Frisell J. Reduced breast cancer mortality after 20+ years of follow-up in the Swedish randomized controlled mammography trials in Malmo, Stockholm, and Goteborg. J Med Screen. 2017;24(1):34–42. [PubMed: 27306511]
218.
Tice JA, Miglioretti DL, Li CS, Vachon CM, Gard CC, Kerlikowske K. Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. J Clin Oncol. 2015;33(28):3137–3143. [PMC free article: PMC4582144] [PubMed: 26282663]
219.
Adams-Campbell LL, Makambi KH, Palmer JR, Rosenberg L. Diagnostic accuracy of the Gail model in the Black Women’s Health Study. Breast J. 2007;13(4):332–336. [PubMed: 17593036]
220.
Gail MH, Anderson WF, Garcia-Closas M, Sherman ME. Absolute risk models for subtypes of breast cancer. Journal of the National Cancer Institute. 2007;99(22):1657–1659. [PubMed: 18000214]
221.
Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. Journal of the National Cancer Institute. 2011;103(12):951–961. [PMC free article: PMC3119648] [PubMed: 21562243]
222.
Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40(11):807–814. [PMC free article: PMC1735317] [PubMed: 14627668]
223.
Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. Journal of the National Cancer Institute. 2007;99(22):1695–1705. [PubMed: 18000216]
224.
Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. Journal of the National Cancer Institute. 2006;98(17):1204–1214. [PubMed: 16954473]
225.
Vacek PM, Skelly JM, Geller BM. Breast cancer risk assessment in women aged 70 and older. Breast Cancer Res Treat. 2011;130(1):291–299. [PubMed: 21604157]
226.
Brentnall AR, Harkness EF, Astley SM, et al. Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Res. 2015;17(1):147. [PMC free article: PMC4665886] [PubMed: 26627479]
227.
Tice JA, Bissell MCS, Miglioretti DL, et al. Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat. 2019;175(2):519–523. [PMC free article: PMC7138025] [PubMed: 30796654]
228.
Nickson C, Procopio P, Velentzis LS, et al. Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women. Breast Cancer Res. 2018;20(1):155. [PMC free article: PMC6302513] [PubMed: 30572910]
229.
MacInnis RJ, Knight JA, Chung WK, et al. Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort. J Natl Cancer Cent. 2021;113(6):785–791. [PMC free article: PMC8168075] [PubMed: 33301022]
230.
Louro J, Roman M, Posso M, et al. Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. PLoS ONE. 2021;16(3):e0248930. [PMC free article: PMC7987139] [PubMed: 33755692]
231.
McCarthy AM, Guan Z, Welch M, et al. Performance of Breast Cancer Risk-Assessment Models in a Large Mammography Cohort. J Natl Cancer Cent. 2020;112(5):489–497. [PMC free article: PMC7225681] [PubMed: 31556450]
232.
Abdolell M, Payne JI, Caines J, et al. Assessing breast cancer risk within the general screening population: developing a breast cancer risk model to identify higher risk women at mammographic screening. Eur Radiol. 2020;30(10):5417–5426. [PubMed: 32358648]
233.
Eriksson M, Czene K, Strand F, et al. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology. 2020;297(2):327–333. [PubMed: 32897160]
234.
Kakileti ST, Madhu HJ, Manjunath G, Wee L, Dekker A, Sampangi S. Personalized risk prediction for breast cancer pre-screening using artificial intelligence and thermal radiomics. Artif Intell Med. 2020;105:101854. [PubMed: 32505418]
235.
Ming C, Viassolo V, Probst-Hensch N, Chappuis P, Dinov I, Katapodi M. Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models [Journal: Article]. Breast Cancer Res. 2019;21(1). doi:10.1186/s13058-019-1158-4. [PMC free article: PMC6585114] [PubMed: 31221197] [CrossRef]
236.
Yala A, Mikhael PG, Strand F, et al. Toward robust mammography-based models for breast cancer risk. Sci Transl Med. 2021;13(578):27. [PubMed: 33504648]
237.
van Veen EM, Brentnall AR, Byers H, et al. Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. JAMA Oncol. 2018;4(4):476–482. [PMC free article: PMC5885189] [PubMed: 29346471]
238.
Lall K, Lepamets M, Palover M, et al. Polygenic prediction of breast cancer: comparison of genetic predictors and implications for risk stratification. BMC Cancer. 2019;19(1):557. [PMC free article: PMC6558751] [PubMed: 31182048]
239.
Mathioudakis AG, Salakari M, Pylkkanen L, et al. Systematic review on women’s values and preferences concerning breast cancer screening and diagnostic services. Psychooncology. 2019;28(5):939–947. [PMC free article: PMC6594004] [PubMed: 30812068]
240.
Mottram R, Knerr WL, Gallacher D, et al. Factors associated with attendance at screening for breast cancer: a systematic review and meta-analysis. BMJ Open. 2021;11(11):e046660. [PMC free article: PMC8634222] [PubMed: 34848507]
241.
Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146(7):502–510. [PubMed: 17404352]
242.
Dabbous FM, Dolecek TA, Berbaum ML, et al. Impact of a False-Positive Screening Mammogram on Subsequent Screening Behavior and Stage at Breast Cancer Diagnosis. Cancer Epidemiol Biomarkers Prev. 2017;26(3):397–403. [PMC free article: PMC5336525] [PubMed: 28183826]
243.
Shi W, Nagler RH, Fowler EF, Gollust SE. Predictors of Women’s Awareness of the Benefits and Harms of Mammography Screening and Associations with Confusion, Ambivalence, and Information Seeking. Health Commun. 2021;36(3):303–314. [PubMed: 31690128]
244.
Hoover DS, Pappadis MR, Housten AJ, et al. Preferences for Communicating about Breast Cancer Screening Among Racially/Ethnically Diverse Older Women. Health Commun. 2019;34(7):702–706. [PMC free article: PMC6062485] [PubMed: 29373069]
245.
Ro V, Jones T, Silverman T, et al. Patient, primary care provider, and stakeholder perspectives on mammography screening frequency: lessons learned from a qualitative study. BMC Cancer. 2022;22(1):819. [PMC free article: PMC9326136] [PubMed: 35897000]
246.
Thomson MD, Siminoff LA. Perspectives on mammography after receipt of secondary screening owing to a false positive. Womens Health Issues. 2015;25(2):128–133. [PMC free article: PMC4355242] [PubMed: 25648490]
247.
Brandzel S, Chang E, Tuzzio L, et al. Latina and Black/African American women’s perspectives on cancer screening and cancer screening reminders. J Racial Ethn Health Disparities. 2016. [PMC free article: PMC5436953] [PubMed: 27864808]
248.
Esmaeili M, Ayyoubzadeh SM, Javanmard Z, S RNK. A systematic review of decision aids for mammography screening: Focus on outcomes and characteristics. Int J Med Inf. 2021;149:104406. [PubMed: 33640838]
249.
Taghian A, Merajver SD. Overview of the treatment of newly diagnosed, invasive, non-metastatic breast cancer. In: Post TW, ed. UpToDate; 2022.
250.
Sharma P. Overview of the approach to metastatic breast cancer. In: Post TW, ed. UpToDate; 2022.
251.
Sabel MS. Breast-conserving therapy. In: Post TW, ed. UpToDate; 2022.
252.
Kwong A, Sabel MS. Mastectomy. In: Post TW, ed. UpToDate; 2022.
253.
Taghian A. Adjuvant radiation therapy for women with newly diagnosed, non-metastatic breast cancer. In: Post TW, ed. UpToDate; 2022.
254.
Shapiro CL. Acute side effects of adjuvant chemotherapy for early-stage breast cancer. In: Post TW, ed. UpToDate; 2022.
255.
Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. Journal of the National Cancer Institute. 2018;110(2). [PMC free article: PMC5825681] [PubMed: 28954296]
256.
Elghazawy H, Venkatesulu BP, Verma V, et al. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies. Crit Rev Oncol Hematol. 2020;153:103006. [PubMed: 32777728]
257.
Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging. 2020;13(1 Pt 2):198–210. [PMC free article: PMC7236624] [PubMed: 31542526]
258.
Chen DH, Tyebally S, Malloupas M, et al. Cardiovascular Disease Amongst Women Treated for Breast Cancer: Traditional Cytotoxic Chemotherapy, Targeted Therapy, and Radiation Therapy. Curr Cardiol Rep. 2021;23(3):16. [PubMed: 33501515]
259.
Stan D, Loprinzi CL, Ruddy KJ. Breast cancer survivorship issues. Hematol Oncol Clin North Am. 2013;27(4):805–827, ix. [PMC free article: PMC3903408] [PubMed: 23915746]
260.
Come SE. Overview of long-term complications of therapy in breast cancer survivors and patterns of relapse. In: Post TW, ed. UpToDate; 2022.
261.
Mannu GS, Wang Z, Broggio J, et al. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ. 2020;369:m1570. [PMC free article: PMC7251423] [PubMed: 32461218]
262.
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888–896. [PubMed: 26291673]
263.
Zhang B, Coopey SB, Gadd MA, Hughes KS, Chang DC, Oseni TO. Trends in unilateral and contralateral prophylactic mastectomy use in ductal carcinoma in situ of the breast: patterns and predictors. Ann Surg Oncol. 2019;26(12):3863–3873. [PubMed: 31325048]
264.
Bouskill K, Hempel S, Richardson A, et al. Evidence map of ductal carcinoma in situ management options. Menopause. 2019;26(11):1250–1258. [PubMed: 31567868]
265.
Hwang ES, Hyslop T, Lynch T, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797. [PMC free article: PMC6429899] [PubMed: 30862637]
266.
Francis A, Fallowfield L, Rea D. The LORIS Trial: Addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol). 2015;27(1):6–8. [PubMed: 25445552]
267.
Solin L. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study [Journal: Short Survey]. Breast diseases. 2016;27(1):47–48. doi:10.1016/j.breastdis.2016.01.009. [PubMed: 26025767] [CrossRef]
268.
Kerlikowske K, Bissell MCS, Sprague BL, et al. Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. J Natl Cancer Cent. 2021;113(7):909–916. [PMC free article: PMC8491791] [PubMed: 33169794]
269.
Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601. [PMC free article: PMC6041728] [PubMed: 30002074]
270.
ECOG-ACRIN Cancer Research Group. EA1151 / TMIST: Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer. https://ecog-acrin​.org​/clinical-trials/ea1151-tmist-breast-cancer-screening-mammography/. Accessed March 8, 2023.
271.
SEER Explorer. Breast Cancer: Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2019. National Institutes of Health and National Cancer Institute. https://seer​.cancer.gov​/explorer/application.html. Published 2022. Accessed February 16, 2023.
272.
Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015;314(15):1599–1614. [PMC free article: PMC4831582] [PubMed: 26501536]
273.
American Academy of Family Physicians. Clinical Preventive Service Recommendation Web site. https://www​.aafp.org​/family-physician/patient-care​/clinical-recommendations​/all-clinical-recommendations/breast-cancer​.html. Published 2020. Accessed Accessed August 26, 2020.
274.
Anonymous. Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstet Gynecol. 2017;130(1):e1–e16. [PubMed: 28644335]
275.
Qaseem A, Lin JS, Mustafa RA, et al. Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. Ann Intern Med. 2019;170(8):547–560. [PubMed: 30959525]
276.
Monticciolo DL, Malak SF, Friedewald SM, et al. Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging. J Am Coll Radiol. 2021;18(9):1280–1288. [PubMed: 34154984]
277.
Women’s Preventive Services Initiative (WPSI). Breast Cancer Screening for Average-Risk Women. https://www​.womenspreventivehealth​.org/recommendations​/breast-cancer-screening-for-average-risk-women/. Published 2020. Accessed Accessed December 4, 2020.
278.
NHS Breast Cancer Screening Programme. Breast screening: programme overview. https://www​.gov.uk/guidance​/breast-screening-programme-overview. Published 2015. Accessed September 3, 2020.
279.
European Commission Initiative on Breast Cancer (ECIBC). European guidelines on breast cancer screening and diagnosis. https:​//healthcare-quality​.jrc.ec.europa​.eu/ecibc/european-breast-cancer-guidelines. Published 2022. Accessed August 18, 2022.
280.
Klarenbach S, Sims-Jones N, Lewin G, et al. Recommendations on screening for breast cancer in women aged 40-74 years who are not at increased risk for breast cancer. CMAJ. 2018;190(49):E1441–E1451. [PMC free article: PMC6279444] [PubMed: 30530611]
281.
Cancer Australia. Early detection of breast cancer. https://www​.canceraustralia​.gov.au/publications-and-resources​/position-statements​/early-detection-breast-cancer. Published 2015. Accessed August 31, 2020.
282.
Habbema JD, van Oortmarssen GJ, van Putten DJ, Lubbe JT, van der Maas PJ. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. Journal of the National Cancer Institute. 1986;77(2):317–320. [PubMed: 3461193]
283.
Miller A, Wall C, Baines C, Sun P, To T, Narod S. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial [Journal: Article]. BMJ 2014;348. doi:10.1136/bmj.g366. [PMC free article: PMC3921437] [PubMed: 24519768] [CrossRef]
284.
Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet. 2006;368(9552):2053–2060. [PubMed: 17161727]
285.
Bjurstam N, Björneld L, Warwick J, et al. The Gothenburg Breast Screening Trial. Cancer. 2003;97(10):2387–2396. [PubMed: 12733136]
286.
Nyström L, Andersson I, Bjurstam N, Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909–919. [PubMed: 11918907]
287.
Tabar L, Fagerberg G, Chen HH, et al. Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer. 1995;75(10):2507–2517. [PubMed: 7736395]
288.
Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L. Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 2016;164(4):256–267. [PubMed: 26756737]
289.
Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 2011;258(1):98–105. [PubMed: 21081671]
290.
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. [PMC free article: PMC5062054] [PubMed: 27733354]
291.
Dale A, Slade E, Heneghan C. Adjunctive ultrasonography for breast cancer screening. The Lancet. 2016;387(10036):2379–2380. [PubMed: 27312305]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (4.1M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...